Trial Outcomes & Findings for The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NCT NCT06665919)
NCT ID: NCT06665919
Last Updated: 2025-09-26
Results Overview
The event of death from any cause reported by the physician according to the WHO Clinical criteria for the determination of death or the incident declared by the caregiver of the patient and checked for appropriateness in hospital registries or the national death registry within the study follow-up period, from the date of study enrollment until the date of the event.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
283 participants
Primary outcome timeframe
within a 12-month of the study follow-up
Results posted on
2025-09-26
Participant Flow
The study investigating CYP2C19 genotype-guided clopidogrel treatment models was conducted by Vistamedi Ltd. (Tbilisi, Georgia) collecting data from out-patient and hospital health care facilities of four clinical cardiology centers in Tbilisi, Georgia. The active recruitment process started after obtaining Institutional Review Boars (IRB) approval of the study protocol and continued for 12 months.
In total, 330 study participants were screened for participation, and 283 who met the study eligibility criteria and signed informed consent forms for study participation were recruited.
Participant milestones
| Measure |
Normal Metabolizers of Clopidogrel
157 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers.
|
Passive Metabolizers of Clopidogrel
43 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping, identified as LoF \*2, \*3 alleles carriers.
|
Unspecified Metabolizers of Clopidogrel
83 participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomization, without CYP2C19 genotyping and clopidogrel metabolism phenotype have not been specified.
|
|---|---|---|---|
|
Overall Study
STARTED
|
157
|
43
|
83
|
|
Overall Study
COMPLETED
|
142
|
38
|
70
|
|
Overall Study
NOT COMPLETED
|
15
|
5
|
13
|
Reasons for withdrawal
| Measure |
Normal Metabolizers of Clopidogrel
157 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers.
|
Passive Metabolizers of Clopidogrel
43 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping, identified as LoF \*2, \*3 alleles carriers.
|
Unspecified Metabolizers of Clopidogrel
83 participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomization, without CYP2C19 genotyping and clopidogrel metabolism phenotype have not been specified.
|
|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
4
|
4
|
4
|
|
Overall Study
Non-compliance to Treatment
|
4
|
1
|
6
|
|
Overall Study
Lost to Follow-up
|
3
|
0
|
2
|
|
Overall Study
Physician Decision
|
4
|
0
|
1
|
Baseline Characteristics
Smoking status patterns among overall, sex-specific and age-specific study participants groups
Baseline characteristics by cohort
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
157 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers.
|
Passive Metabolizers of Clopidogrel
n=43 Participants
43 study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping, identified as LoF \*2, \*3 alleles carriers.
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
83 participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomization, without CYP2C19 genotyping and clopidogrel metabolism phenotype have not been specified.
|
Total
n=283 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Smoking status of study participants
50-64 years old study participants · Current Smoker
|
34 Participants
n=62 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
8 Participants
n=17 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
29 Participants
n=33 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
71 Participants
n=112 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
50-64 years old study participants · Former Smoker
|
20 Participants
n=62 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
7 Participants
n=17 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
3 Participants
n=33 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
30 Participants
n=112 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Age, Continuous
mean age of overall study participants
|
63.91 years
STANDARD_DEVIATION 9.03 • n=157 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
66.35 years
STANDARD_DEVIATION 7.34 • n=43 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
63.49 years
STANDARD_DEVIATION 9.96 • n=83 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
64.16 years
STANDARD_DEVIATION 9.10 • n=283 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
|
Age, Continuous
mean age of female study participants
|
68.73 years
STANDARD_DEVIATION 7.15 • n=56 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
69.25 years
STANDARD_DEVIATION 6.96 • n=20 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
67.80 years
STANDARD_DEVIATION 8.05 • n=30 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
68.57 years
STANDARD_DEVIATION 7.33 • n=106 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
|
Age, Continuous
mean age of male study participants
|
61.24 years
STANDARD_DEVIATION 8.88 • n=101 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
63.83 years
STANDARD_DEVIATION 6.84 • n=23 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
61.06 years
STANDARD_DEVIATION 10.18 • n=53 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
61.52 years
STANDARD_DEVIATION 9.06 • n=177 Participants • The mean age of study arm participants is given for overall and sex-specific groups
|
|
Age, Customized
Age ranges of study participants · 35-49 years old
|
13 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
8 Participants
n=83 Participants
|
21 Participants
n=283 Participants
|
|
Age, Customized
Age ranges of study participants · 50-64 years old
|
62 Participants
n=157 Participants
|
17 Participants
n=43 Participants
|
33 Participants
n=83 Participants
|
112 Participants
n=283 Participants
|
|
Age, Customized
Age ranges of study participants · 65-79 years old
|
82 Participants
n=157 Participants
|
26 Participants
n=43 Participants
|
42 Participants
n=83 Participants
|
150 Participants
n=283 Participants
|
|
Sex: Female, Male
Female
|
56 Participants
n=157 Participants
|
20 Participants
n=43 Participants
|
30 Participants
n=83 Participants
|
106 Participants
n=283 Participants
|
|
Sex: Female, Male
Male
|
101 Participants
n=157 Participants
|
23 Participants
n=43 Participants
|
53 Participants
n=83 Participants
|
177 Participants
n=283 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Race (NIH/OMB)
White
|
157 Participants
n=157 Participants
|
43 Participants
n=43 Participants
|
83 Participants
n=83 Participants
|
283 Participants
n=283 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
0 Participants
n=283 Participants
|
|
Region of Enrollment
Georgia
|
157 Participants
n=157 Participants
|
43 Participants
n=43 Participants
|
83 Participants
n=83 Participants
|
283 Participants
n=283 Participants
|
|
Smoking status of study participants
Overall study participants · Current Smoker
|
58 Participants
n=157 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
14 Participants
n=43 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
50 Participants
n=83 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
122 Participants
n=283 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Overall study participants · Former Smoker
|
57 Participants
n=157 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
16 Participants
n=43 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
14 Participants
n=83 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
87 Participants
n=283 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Overall study participants · Never Smoker
|
42 Participants
n=157 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
13 Participants
n=43 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
19 Participants
n=83 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
74 Participants
n=283 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Female study participants · Current Smoker
|
7 Participants
n=56 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
1 Participants
n=20 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
7 Participants
n=30 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
15 Participants
n=106 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Doppler- echocardiographic characteristics
Aortic valve calcification
|
27 Participants
n=157 Participants
|
8 Participants
n=43 Participants
|
23 Participants
n=83 Participants
|
58 Participants
n=283 Participants
|
|
Smoking status of study participants
Female study participants · Former Smoker
|
12 Participants
n=56 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
6 Participants
n=20 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
5 Participants
n=30 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
23 Participants
n=106 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Female study participants · Never Smoker
|
37 Participants
n=56 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
13 Participants
n=20 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
18 Participants
n=30 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
68 Participants
n=106 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Male study participants · Current Smoker
|
51 Participants
n=101 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
13 Participants
n=23 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
43 Participants
n=53 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
107 Participants
n=177 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Male study participants · Former Smoker
|
45 Participants
n=101 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
10 Participants
n=23 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
9 Participants
n=53 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
64 Participants
n=177 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
Male study participants · Never Smoker
|
5 Participants
n=101 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
0 Participants
n=23 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
1 Participants
n=53 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
6 Participants
n=177 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
35-49 years old study participants · Current Smoker
|
8 Participants
n=13 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
0 Participants
Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
7 Participants
n=8 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
15 Participants
n=21 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
35-49 years old study participants · Former Smoker
|
4 Participants
n=13 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
0 Participants
Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
1 Participants
n=8 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
5 Participants
n=21 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
35-49 years old study participants · Never Smoker
|
1 Participants
n=13 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
0 Participants
Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
0 Participants
n=8 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
1 Participants
n=21 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Symptom manifestations/conditions prior to index PCI
Angina
|
107 Participants
n=157 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
28 Participants
n=43 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
76 Participants
n=83 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
211 Participants
n=283 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Smoking status of study participants
50-64 years old study participants · Never Smoker
|
8 Participants
n=62 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
2 Participants
n=17 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
1 Participants
n=33 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
11 Participants
n=112 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Doppler- echocardiographic characteristics
Secondary (functional) mitral regurgitation
|
123 Participants
n=157 Participants
|
36 Participants
n=43 Participants
|
69 Participants
n=83 Participants
|
228 Participants
n=283 Participants
|
|
Smoking status of study participants
65-79 years old study participants · Current Smoker
|
16 Participants
n=82 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
6 Participants
n=26 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
14 Participants
n=42 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
36 Participants
n=150 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
65-79 years old study participants · Former Smoker
|
33 Participants
n=82 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
9 Participants
n=26 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
10 Participants
n=42 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
52 Participants
n=150 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Smoking status of study participants
65-79 years old study participants · Never Smoker
|
33 Participants
n=82 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
11 Participants
n=26 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
18 Participants
n=42 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
62 Participants
n=150 Participants • Smoking status patterns among overall, sex-specific and age-specific study participants groups
|
|
Obesity among study participants
Overall study participants
|
91 Participants
n=157 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
21 Participants
n=43 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
48 Participants
n=83 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
160 Participants
n=283 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Obesity among study participants
Female study participants
|
31 Participants
n=56 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
10 Participants
n=20 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
22 Participants
n=30 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
63 Participants
n=106 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Obesity among study participants
Male study participants
|
60 Participants
n=101 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
11 Participants
n=23 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
26 Participants
n=53 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
97 Participants
n=177 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Obesity among study participants
35-49 years study participants
|
7 Participants
n=13 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
0 Participants
Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
6 Participants
n=8 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
13 Participants
n=21 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Obesity among study participants
50-64 years old study participants
|
53 Participants
n=62 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
8 Participants
n=17 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
17 Participants
n=33 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
78 Participants
n=112 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Obesity among study participants
65-79 years old study participants
|
41 Participants
n=82 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
13 Participants
n=26 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
25 Participants
n=42 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
79 Participants
n=150 Participants • Number and percentage of obese study participants in the overall, sex- and age-specific groups
|
|
Body Mass Index (BMI) of study participants
Overall study participants
|
30.5 kg/m^2
STANDARD_DEVIATION 4.32 • n=157 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.5 kg/m^2
STANDARD_DEVIATION 4.67 • n=43 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
31.0 kg/m^2
STANDARD_DEVIATION 3.65 • n=83 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.6 kg/m^2
STANDARD_DEVIATION 4.18 • n=283 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Body Mass Index (BMI) of study participants
Female study participants
|
30.2 kg/m^2
STANDARD_DEVIATION 4.62 • n=56 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.5 kg/m^2
STANDARD_DEVIATION 4.88 • n=20 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
31.7 kg/m^2
STANDARD_DEVIATION 3.12 • n=30 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.7 kg/m^2
STANDARD_DEVIATION 4.31 • n=106 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Body Mass Index (BMI) of study participants
Male study participants
|
30.6 kg/m^2
STANDARD_DEVIATION 4.17 • n=101 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.5 kg/m^2
STANDARD_DEVIATION 4.58 • n=23 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.57 kg/m^2
STANDARD_DEVIATION 3.89 • n=53 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.6 kg/m^2
STANDARD_DEVIATION 4.12 • n=177 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Body Mass Index (BMI) of study participants
35-49 years old study participants
|
30.2 kg/m^2
STANDARD_DEVIATION 4.69 • n=13 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
—
|
31.6 kg/m^2
STANDARD_DEVIATION 3.70 • n=8 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.7 kg/m^2
STANDARD_DEVIATION 4.30 • n=21 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Body Mass Index (BMI) of study participants
50-64 years old study participants
|
31.3 kg/m^2
STANDARD_DEVIATION 4.00 • n=62 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.8 kg/m^2
STANDARD_DEVIATION 5.20 • n=17 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.6 kg/m^2
STANDARD_DEVIATION 2.90 • n=33 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
31.00 kg/m^2
STANDARD_DEVIATION 3.90 • n=112 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Body Mass Index (BMI) of study participants
65-79 years old study participants
|
29.9 kg/m^2
STANDARD_DEVIATION 4.46 • n=82 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.3 kg/m^2
STANDARD_DEVIATION 4.38 • n=26 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
31.1 kg/m^2
STANDARD_DEVIATION 4.18 • n=42 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
30.3 kg/m^2
STANDARD_DEVIATION 4.37 • n=150 Participants • The mean BMI (kg/m\^2) of overall, sex- and age-specific group study participants
|
|
Blood Pressure control
Overall study participants · with Controlled BP
|
89 Participants
n=157 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
28 Participants
n=43 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
21 Participants
n=83 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
138 Participants
n=283 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
Overall study participants · with Uncontrolled BP
|
68 Participants
n=157 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
15 Participants
n=43 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
62 Participants
n=83 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
145 Participants
n=283 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
Female study participants · with Controlled BP
|
31 Participants
n=56 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
13 Participants
n=20 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
7 Participants
n=30 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
51 Participants
n=106 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
Female study participants · with Uncontrolled BP
|
25 Participants
n=56 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
7 Participants
n=20 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
23 Participants
n=30 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
55 Participants
n=106 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
Male study participants · with Controlled BP
|
58 Participants
n=101 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
15 Participants
n=23 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
14 Participants
n=53 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
87 Participants
n=177 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
Male study participants · with Uncontrolled BP
|
43 Participants
n=101 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
8 Participants
n=23 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
39 Participants
n=53 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
90 Participants
n=177 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
35-49 years old study participants · with Controlled BP
|
8 Participants
n=13 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
0 Participants
Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
5 Participants
n=8 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
13 Participants
n=21 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
35-49 years old study participants · with Uncontrolled BP
|
5 Participants
n=13 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
0 Participants
Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
3 Participants
n=8 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
8 Participants
n=21 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
50-64 years old study participants · with Controlled BP
|
34 Participants
n=62 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
11 Participants
n=17 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
8 Participants
n=33 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
53 Participants
n=112 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
50-64 years old study participants · with Uncontrolled BP
|
28 Participants
n=62 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
6 Participants
n=17 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
25 Participants
n=33 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
59 Participants
n=112 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
65-79 years old study participants · with Controlled BP
|
47 Participants
n=82 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
17 Participants
n=26 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
8 Participants
n=42 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
72 Participants
n=150 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
Blood Pressure control
65-79 years old study participants · with Uncontrolled BP
|
35 Participants
n=82 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
9 Participants
n=26 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
34 Participants
n=42 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
78 Participants
n=150 Participants • Number and percentage of study participants with controlled and uncontrolled blood pressure in the overall, and sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of overall study participants
|
138.1 mmHg
STANDARD_DEVIATION 21.44 • n=157 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
134.1 mmHg
STANDARD_DEVIATION 19.57 • n=43 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
149.0 mmHg
STANDARD_DEVIATION 16.27 • n=83 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
140.7 mmHg
STANDARD_DEVIATION 20.47 • n=283 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of overall study participants
|
82.4 mmHg
STANDARD_DEVIATION 12.19 • n=157 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
79.6 mmHg
STANDARD_DEVIATION 12.45 • n=43 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
89.3 mmHg
STANDARD_DEVIATION 10.52 • n=83 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
84.0 mmHg
STANDARD_DEVIATION 12.25 • n=283 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of female study participants
|
139.1 mmHg
STANDARD_DEVIATION 22.64 • n=56 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
135.9 mmHg
STANDARD_DEVIATION 20.27 • n=20 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
150.1 mmHg
STANDARD_DEVIATION 17.84 • n=30 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
141.6 mmHg
STANDARD_DEVIATION 21.47 • n=106 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of female study participants
|
82.7 mmHg
STANDARD_DEVIATION 11.75 • n=56 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
78.7 mmHg
STANDARD_DEVIATION 12.89 • n=20 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
88.6 mmHg
STANDARD_DEVIATION 10.20 • n=30 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
83.6 mmHg
STANDARD_DEVIATION 11.97 • n=106 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of male study participants
|
137.5 mmHg
STANDARD_DEVIATION 20.83 • n=101 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
132.5 mmHg
STANDARD_DEVIATION 19.26 • n=23 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
148.3 mmHg
STANDARD_DEVIATION 15.45 • n=53 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
140.1 mmHg
STANDARD_DEVIATION 19.88 • n=177 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of male study participant
|
82.2 mmHg
STANDARD_DEVIATION 12.47 • n=101 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
80.4 mmHg
STANDARD_DEVIATION 12.28 • n=23 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
89.7 mmHg
STANDARD_DEVIATION 10.77 • n=53 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
84.2 mmHg
STANDARD_DEVIATION 12.44 • n=177 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of 35-49 years old study participants
|
129.5 mmHg
STANDARD_DEVIATION 12.61 • n=13 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
—
|
135.0 mmHg
STANDARD_DEVIATION 15.34 • n=8 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
131.6 mmHg
STANDARD_DEVIATION 13.62 • n=21 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of 35-49 years old study participants
|
83.8 mmHg
STANDARD_DEVIATION 10.34 • n=13 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
—
|
83.5 mmHg
STANDARD_DEVIATION 12.50 • n=8 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
83.7 mmHg
STANDARD_DEVIATION 10.90 • n=21 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of 50-64 years old study participant
|
139.9 mmHg
STANDARD_DEVIATION 21.55 • n=62 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
133.7 mmHg
STANDARD_DEVIATION 20.01 • n=17 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
150.4 mmHg
STANDARD_DEVIATION 16.16 • n=33 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
142.1 mmHg
STANDARD_DEVIATION 20.55 • n=112 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of 50-64 years old study participants
|
83.3 mmHg
STANDARD_DEVIATION 13.51 • n=62 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
80.5 mmHg
STANDARD_DEVIATION 12.97 • n=17 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
91.3 mmHg
STANDARD_DEVIATION 10.74 • n=33 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
85.2 mmHg
STANDARD_DEVIATION 13.22 • n=112 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
SBP of 65-79 years old study participants
|
138.0 mmHg
STANDARD_DEVIATION 22.31 • n=82 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
134.3 mmHg
STANDARD_DEVIATION 19.68 • n=26 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
150.5 mmHg
STANDARD_DEVIATION 15.59 • n=42 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
140.8 mmHg
STANDARD_DEVIATION 20.98 • n=150 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
BP measurement results of study participants
DBP of 65-79 years old study participants
|
81.5 mmHg
STANDARD_DEVIATION 11.45 • n=82 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
79.1 mmHg
STANDARD_DEVIATION 12.32 • n=26 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
88.8 mmHg
STANDARD_DEVIATION 9.71 • n=42 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
83.1 mmHg
STANDARD_DEVIATION 11.67 • n=150 Participants • The mean SBP and DBP (mmHg) of study participants overall, and by sex- and age-specific groups
|
|
Type 2 Diabetes Mellitus
Overall study participants · Uncontrolled T2DM
|
59 Participants
n=157 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
16 Participants
n=43 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
40 Participants
n=83 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
115 Participants
n=283 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Overall study participants · Controlled T2DM
|
30 Participants
n=157 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
8 Participants
n=43 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
3 Participants
n=83 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
41 Participants
n=283 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Overall study participants · No T2DM
|
68 Participants
n=157 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
19 Participants
n=43 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
40 Participants
n=83 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
127 Participants
n=283 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Female study participants · Uncontrolled T2DM
|
16 Participants
n=56 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
10 Participants
n=20 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
16 Participants
n=30 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
42 Participants
n=106 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Female study participants · Controlled T2DM
|
15 Participants
n=56 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
4 Participants
n=20 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
1 Participants
n=30 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
20 Participants
n=106 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Female study participants · No T2DM
|
25 Participants
n=56 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
6 Participants
n=20 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
13 Participants
n=30 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
44 Participants
n=106 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Male study participants · Uncontrolled T2DM
|
43 Participants
n=101 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
6 Participants
n=23 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
24 Participants
n=53 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
73 Participants
n=177 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Male study participants · Controlled T2DM
|
15 Participants
n=101 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
4 Participants
n=23 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
2 Participants
n=53 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
21 Participants
n=177 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
Male study participants · No T2DM
|
43 Participants
n=101 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
13 Participants
n=23 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
27 Participants
n=53 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
83 Participants
n=177 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
35-49 years old study participants · Uncontrolled T2DM
|
6 Participants
n=13 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
0 Participants
Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
2 Participants
n=8 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
8 Participants
n=21 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
35-49 years old study participants · Controlled T2DM
|
0 Participants
n=13 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
0 Participants
Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
1 Participants
n=8 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
1 Participants
n=21 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
35-49 years old study participants · No T2DM
|
7 Participants
n=13 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
0 Participants
Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
5 Participants
n=8 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
12 Participants
n=21 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
40-64 years old study participants · Uncontrolled T2DM
|
26 Participants
n=62 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
5 Participants
n=17 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
15 Participants
n=33 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
46 Participants
n=112 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
40-64 years old study participants · Controlled T2DM
|
12 Participants
n=62 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
1 Participants
n=17 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
2 Participants
n=33 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
15 Participants
n=112 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
40-64 years old study participants · No T2DM
|
24 Participants
n=62 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
11 Participants
n=17 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
16 Participants
n=33 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
51 Participants
n=112 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
65-79 years old study participants · Uncontrolled T2DM
|
27 Participants
n=82 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
11 Participants
n=26 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
23 Participants
n=42 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
61 Participants
n=150 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
65-79 years old study participants · Controlled T2DM
|
18 Participants
n=82 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
7 Participants
n=26 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
0 Participants
n=42 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
25 Participants
n=150 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Type 2 Diabetes Mellitus
65-79 years old study participants · No T2DM
|
37 Participants
n=82 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
8 Participants
n=26 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
19 Participants
n=42 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
64 Participants
n=150 Participants • Number and percentage of study participants with Uncontrolled, Controlled and No T2DM in overall, by sex- and age-specific arms at the time of enrollment
|
|
Glycated Hemoglobin (HbA1c) Levels
Overall study participants
|
6.3 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.94 • n=157 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.3 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.01 • n=43 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.13 • n=83 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.01 • n=283 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Glycated Hemoglobin (HbA1c) Levels
Female study participants
|
6.1 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.78 • n=56 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.7 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.12 • n=20 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.6 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.23 • n=30 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.02 • n=106 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Glycated Hemoglobin (HbA1c) Levels
Male study participants
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.01 • n=101 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.0 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.78 • n=23 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.08 • n=53 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.95 • n=177 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Glycated Hemoglobin (HbA1c) Levels
35-49 years old study participants
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.07 • n=13 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
—
|
6.2 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.11 • n=8 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.07 • n=21 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Glycated Hemoglobin (HbA1c) Levels
50-64 years old study participants
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.05 • n=62 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.1 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.97 • n=17 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.13 • n=33 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.06 • n=112 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Glycated Hemoglobin (HbA1c) Levels
65-79 years old study participants
|
6.2 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.83 • n=82 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.5 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.01 • n=26 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.7 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 1.15 • n=42 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
6.4 percentage (%) of glycated hemoglobin
STANDARD_DEVIATION 0.98 • n=150 Participants • Mean HbA1c measurement results (in %) of study participants overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Overall study participants · Uncontrolled LDL-C Level
|
92 Participants
n=157 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
18 Participants
n=43 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
71 Participants
n=83 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
181 Participants
n=283 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Overall study participants · Controlled LDL-C Level
|
65 Participants
n=157 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
25 Participants
n=43 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
12 Participants
n=83 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
102 Participants
n=283 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Female study participants · Uncontrolled LDL-C Level
|
32 Participants
n=56 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
7 Participants
n=20 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
28 Participants
n=30 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
67 Participants
n=106 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Female study participants · Controlled LDL-C Level
|
24 Participants
n=56 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
13 Participants
n=20 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
2 Participants
n=30 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
39 Participants
n=106 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Male study participants · Uncontrolled LDL-C Level
|
60 Participants
n=101 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
11 Participants
n=23 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
43 Participants
n=53 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
114 Participants
n=177 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
Male study participants · Controlled LDL-C Level
|
41 Participants
n=101 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
12 Participants
n=23 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
10 Participants
n=53 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
63 Participants
n=177 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
35-49 years old study participants · Uncontrolled LDL-C Level
|
9 Participants
n=13 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
0 Participants
Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
4 Participants
n=8 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
13 Participants
n=21 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
35-49 years old study participants · Controlled LDL-C Level
|
4 Participants
n=13 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
0 Participants
Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
4 Participants
n=8 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
8 Participants
n=21 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
50-64 years old study participants · Uncontrolled LDL-C Level
|
33 Participants
n=62 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
5 Participants
n=17 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
29 Participants
n=33 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
67 Participants
n=112 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
50-64 years old study participants · Controlled LDL-C Level
|
29 Participants
n=62 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
12 Participants
n=17 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
4 Participants
n=33 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
45 Participants
n=112 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
65-79 years old study participants · Uncontrolled LDL-C Level
|
50 Participants
n=82 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
13 Participants
n=26 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
38 Participants
n=42 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
101 Participants
n=150 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Low Density Lipoprotein Cholesterol (LDL-C) Controlling Status
65-79 years old study participants · Controlled LDL-C Level
|
32 Participants
n=82 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
13 Participants
n=26 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
4 Participants
n=42 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
49 Participants
n=150 Participants • Number and percentage of study participants with uncontrolled and controlled LDL-C levels in the overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
Overall study participants
|
94.6 mg/dl
STANDARD_DEVIATION 51.59 • n=157 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
77.6 mg/dl
STANDARD_DEVIATION 42.59 • n=43 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
117.5 mg/dl
STANDARD_DEVIATION 35.56 • n=83 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
98.7 mg/dl
STANDARD_DEVIATION 47.87 • n=283 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
Female study participants
|
91.8 mg/dl
STANDARD_DEVIATION 48.85 • n=56 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
73.2 mg/dl
STANDARD_DEVIATION 39.87 • n=20 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
119.9 mg/dl
STANDARD_DEVIATION 25.49 • n=30 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
96.2 mg/dl
STANDARD_DEVIATION 44.59 • n=106 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
Male study participants
|
96.1 mg/dl
STANDARD_DEVIATION 53.23 • n=101 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
81.4 mg/dl
STANDARD_DEVIATION 45.35 • n=23 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
116.1 mg/dl
STANDARD_DEVIATION 40.33 • n=53 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
100.2 mg/dl
STANDARD_DEVIATION 49.80 • n=177 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
35-49 years old study participants
|
99.5 mg/dl
STANDARD_DEVIATION 57.12 • n=13 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
—
|
95.6 mg/dl
STANDARD_DEVIATION 55.01 • n=8 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
98.0 mg/dl
STANDARD_DEVIATION 55.03 • n=21 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
50-64 years old study participants
|
95.0 mg/dl
STANDARD_DEVIATION 53.93 • n=62 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
70.3 mg/dl
STANDARD_DEVIATION 46.2 • n=17 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
118.3 mg/dl
STANDARD_DEVIATION 34.45 • n=33 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
98.1 mg/dl
STANDARD_DEVIATION 49.93 • n=112 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Serum LDL-C measurement results
65-79 years old study participants
|
93.5 mg/dl
STANDARD_DEVIATION 49.47 • n=82 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
82.4 mg/dl
STANDARD_DEVIATION 40.26 • n=26 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
121.0 mg/dl
STANDARD_DEVIATION 31.29 • n=42 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
99.3 mg/dl
STANDARD_DEVIATION 45.54 • n=150 Participants • The mean LDL-C level of study participants overall, and by sex- and age-specific groups
|
|
Symptom manifestations/conditions prior to index PCI
No angina
|
50 Participants
n=157 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
15 Participants
n=43 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
7 Participants
n=83 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
72 Participants
n=283 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Heart Failure Event
|
22 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
5 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
5 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
32 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Supraventricular Tachycardia
|
5 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
2 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
1 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
8 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Atrial Fibrillation
|
7 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
2 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
0 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
9 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Premature Ventricular Contraction/Ventricular tachycardia
|
1 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
1 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
0 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
2 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Left Bundle Branch Block
|
2 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
0 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
0 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
2 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
Symptom manifestations/conditions prior to index PCI
Other non-specific symptoms
|
13 Participants
n=50 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
5 Participants
n=15 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
1 Participants
n=7 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
19 Participants
n=72 Participants • Number and percentage of study participants with angina and other clinical conditions considered as the reason for the most recent PCI
|
|
History of Cardiovascular Morbidity
Prior Myocardium Infarction
|
83 Participants
n=157 Participants
|
21 Participants
n=43 Participants
|
40 Participants
n=83 Participants
|
144 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Chronic Heart Failure
|
50 Participants
n=157 Participants
|
13 Participants
n=43 Participants
|
29 Participants
n=83 Participants
|
92 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Supraventricular tachycardia - paroxysmal
|
29 Participants
n=157 Participants
|
6 Participants
n=43 Participants
|
2 Participants
n=83 Participants
|
37 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Supraventricular tachycardia - paroxysmal, recurrent
|
6 Participants
n=157 Participants
|
4 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
10 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Atrial Fibrillation - Paroxysmal
|
3 Participants
n=157 Participants
|
1 Participants
n=43 Participants
|
2 Participants
n=83 Participants
|
6 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Atrial Fibrillation - Persistent
|
23 Participants
n=157 Participants
|
6 Participants
n=43 Participants
|
5 Participants
n=83 Participants
|
34 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Atrial Fibrillation - Permanent
|
5 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
4 Participants
n=83 Participants
|
11 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Premature Ventricular Contraction
|
135 Participants
n=157 Participants
|
35 Participants
n=43 Participants
|
80 Participants
n=83 Participants
|
250 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Ventricular Tachycardia
|
25 Participants
n=157 Participants
|
5 Participants
n=43 Participants
|
4 Participants
n=83 Participants
|
34 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Ventricular Fibrillation Event
|
8 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
1 Participants
n=83 Participants
|
9 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Sinus Node Disfunction
|
4 Participants
n=157 Participants
|
1 Participants
n=43 Participants
|
1 Participants
n=83 Participants
|
6 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
AV Block
|
10 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
3 Participants
n=83 Participants
|
13 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Left Bundle Branch Block
|
19 Participants
n=157 Participants
|
4 Participants
n=43 Participants
|
17 Participants
n=83 Participants
|
40 Participants
n=283 Participants
|
|
History of Cardiovascular Morbidity
Bight Bundle Branch Block
|
40 Participants
n=157 Participants
|
18 Participants
n=43 Participants
|
23 Participants
n=83 Participants
|
81 Participants
n=283 Participants
|
|
Coronary artery bypass grafting
|
21 Participants
n=157 Participants
|
5 Participants
n=43 Participants
|
7 Participants
n=83 Participants
|
33 Participants
n=283 Participants
|
|
Major Coronary Vascular Event
Number of Prior MI events
|
0.53 number of events
STANDARD_DEVIATION 0.51 • n=157 Participants
|
0.49 number of events
STANDARD_DEVIATION 0.51 • n=43 Participants
|
0.55 number of events
STANDARD_DEVIATION 0.63 • n=83 Participants
|
0.53 number of events
STANDARD_DEVIATION 0.53 • n=283 Participants
|
|
Major Coronary Vascular Event
Number of PCIs
|
1.55 number of events
STANDARD_DEVIATION 0.58 • n=157 Participants
|
1.56 number of events
STANDARD_DEVIATION 0.67 • n=43 Participants
|
1.75 number of events
STANDARD_DEVIATION 0.71 • n=83 Participants
|
1.61 number of events
STANDARD_DEVIATION 0.64 • n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Peripheral Artery Disease without intravascular intervention
|
15 Participants
n=157 Participants
|
7 Participants
n=43 Participants
|
9 Participants
n=83 Participants
|
31 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Peripheral Artery Disease with endarterectomy
|
2 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
1 Participants
n=83 Participants
|
3 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Peripheral Artery Disease with stenting
|
6 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
11 Participants
n=83 Participants
|
19 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Peripheral Artery Disease with endarterectomy and stenting
|
3 Participants
n=157 Participants
|
1 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
4 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Carotid Artery Disease without intravascular intervention
|
36 Participants
n=157 Participants
|
9 Participants
n=43 Participants
|
22 Participants
n=83 Participants
|
67 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Carotid Artery Disease with endarterectomy
|
4 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
8 Participants
n=83 Participants
|
12 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Carotid Artery Disease with stenting
|
1 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
3 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Carotid Artery Disease with endarterectomy and stenting
|
2 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
2 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Cerebrovascular Disease with minor stroke
|
14 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
16 Participants
n=283 Participants
|
|
Atherosclerotic vascular co-morbid diseases/conditions
Cerebrovascular Disease with TIA
|
51 Participants
n=157 Participants
|
15 Participants
n=43 Participants
|
30 Participants
n=83 Participants
|
96 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Chronic Obstructive Pulmonary Disease
|
55 Participants
n=157 Participants
|
13 Participants
n=43 Participants
|
26 Participants
n=83 Participants
|
94 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Chronic Kidney Disease
|
36 Participants
n=157 Participants
|
8 Participants
n=43 Participants
|
26 Participants
n=83 Participants
|
70 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Peptic Ulcer
|
21 Participants
n=157 Participants
|
11 Participants
n=43 Participants
|
12 Participants
n=83 Participants
|
44 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Chronic Gastritis
|
59 Participants
n=157 Participants
|
18 Participants
n=43 Participants
|
30 Participants
n=83 Participants
|
107 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
GI Bleeding Event
|
7 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
6 Participants
n=83 Participants
|
15 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Cured Cancer
|
14 Participants
n=157 Participants
|
5 Participants
n=43 Participants
|
8 Participants
n=83 Participants
|
27 Participants
n=283 Participants
|
|
Other co-morbid diseases/conditions
Thyroid Disease
|
25 Participants
n=157 Participants
|
8 Participants
n=43 Participants
|
5 Participants
n=83 Participants
|
38 Participants
n=283 Participants
|
|
Coronary Artery Lesion
Total Number of Coronary Artery Lesion Sites
|
4.01 Coronary artery lesions
STANDARD_DEVIATION 1.10 • n=157 Participants
|
3.79 Coronary artery lesions
STANDARD_DEVIATION 1.13 • n=43 Participants
|
4.17 Coronary artery lesions
STANDARD_DEVIATION 1.09 • n=83 Participants
|
4.01 Coronary artery lesions
STANDARD_DEVIATION 1.10 • n=283 Participants
|
|
Coronary Artery Lesion
Number of Haemodynamically Significant Coronary Artery Lesion Sites
|
2.53 Coronary artery lesions
STANDARD_DEVIATION 1.21 • n=157 Participants
|
2.23 Coronary artery lesions
STANDARD_DEVIATION 0.95 • n=43 Participants
|
2.54 Coronary artery lesions
STANDARD_DEVIATION 1.10 • n=83 Participants
|
2.49 Coronary artery lesions
STANDARD_DEVIATION 1.14 • n=283 Participants
|
|
Intracoronary Stenting History
|
2.17 number of stents
STANDARD_DEVIATION 0.88 • n=157 Participants
|
2.09 number of stents
STANDARD_DEVIATION 0.72 • n=43 Participants
|
2.33 number of stents
STANDARD_DEVIATION 0.98 • n=83 Participants
|
2.20 number of stents
STANDARD_DEVIATION 0.89 • n=283 Participants
|
|
Coronary Artery Anatomy
Left main coronary artery : Obstructive
|
5 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
5 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Left main coronary artery : Non-obstructive
|
6 Participants
n=157 Participants
|
3 Participants
n=43 Participants
|
4 Participants
n=83 Participants
|
13 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Left anterior descending artery : Obstructive
|
105 Participants
n=157 Participants
|
30 Participants
n=43 Participants
|
52 Participants
n=83 Participants
|
187 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Left anterior descending artery : Non-obstructive
|
15 Participants
n=157 Participants
|
5 Participants
n=43 Participants
|
11 Participants
n=83 Participants
|
31 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
1st diagonal branch of the left anterior descending coronary artery : Obstructive
|
56 Participants
n=157 Participants
|
12 Participants
n=43 Participants
|
29 Participants
n=83 Participants
|
97 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
1st diagonal branch of the left anterior descending coronary artery : Non-obstructive
|
30 Participants
n=157 Participants
|
7 Participants
n=43 Participants
|
17 Participants
n=83 Participants
|
54 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
2nd diagonal branch of the left anterior descending coronary artery : Obstructive
|
4 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
3 Participants
n=83 Participants
|
9 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
2nd diagonal branch of the left anterior descending coronary artery : Non-obstructive
|
9 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
7 Participants
n=83 Participants
|
18 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Left circumflex artery : Obstructive
|
104 Participants
n=157 Participants
|
26 Participants
n=43 Participants
|
53 Participants
n=83 Participants
|
183 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Left circumflex artery : Non-obstructive
|
26 Participants
n=157 Participants
|
12 Participants
n=43 Participants
|
17 Participants
n=83 Participants
|
55 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
1st Marginal arteries : Obstructive
|
40 Participants
n=157 Participants
|
9 Participants
n=43 Participants
|
24 Participants
n=83 Participants
|
73 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
1st Marginal arteries : Non-obstructive
|
39 Participants
n=157 Participants
|
14 Participants
n=43 Participants
|
29 Participants
n=83 Participants
|
82 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
2nd Marginal arteries : Obstructive
|
1 Participants
n=157 Participants
|
1 Participants
n=43 Participants
|
1 Participants
n=83 Participants
|
3 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
2nd Marginal arteries : Non-obstructive
|
7 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
3 Participants
n=83 Participants
|
10 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Right coronary artery : Obstructive
|
75 Participants
n=157 Participants
|
20 Participants
n=43 Participants
|
34 Participants
n=83 Participants
|
129 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Right coronary artery : Non-obstructive
|
44 Participants
n=157 Participants
|
15 Participants
n=43 Participants
|
25 Participants
n=83 Participants
|
84 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Right marginal branch of right coronary artery : Obstructive
|
1 Participants
n=157 Participants
|
0 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
1 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Right marginal branch of right coronary artery : Non-obstructive
|
2 Participants
n=157 Participants
|
1 Participants
n=43 Participants
|
0 Participants
n=83 Participants
|
3 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Posterior descending artery : Obstructive
|
12 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
15 Participants
n=83 Participants
|
29 Participants
n=283 Participants
|
|
Coronary Artery Anatomy
Posterior descending artery : Non-obstructive
|
13 Participants
n=157 Participants
|
2 Participants
n=43 Participants
|
8 Participants
n=83 Participants
|
23 Participants
n=283 Participants
|
|
Echocardiographic Linear Dimensions
Left ventricular posterior wall thickness
|
11.45 millimeter
STANDARD_DEVIATION 1.22 • n=157 Participants
|
11.30 millimeter
STANDARD_DEVIATION 1.01 • n=43 Participants
|
11.54 millimeter
STANDARD_DEVIATION 1.73 • n=83 Participants
|
11.46 millimeter
STANDARD_DEVIATION 1.86 • n=283 Participants
|
|
Echocardiographic Linear Dimensions
Interventricular septum thickness
|
12.04 millimeter
STANDARD_DEVIATION 1.33 • n=157 Participants
|
11.88 millimeter
STANDARD_DEVIATION 1.14 • n=43 Participants
|
12.49 millimeter
STANDARD_DEVIATION 1.84 • n=83 Participants
|
12.15 millimeter
STANDARD_DEVIATION 1.49 • n=283 Participants
|
|
Echocardiographic Linear Dimensions
Left ventricular end-diastolic diameter
|
49.64 millimeter
STANDARD_DEVIATION 5.49 • n=157 Participants
|
48.02 millimeter
STANDARD_DEVIATION 4.07 • n=43 Participants
|
50.41 millimeter
STANDARD_DEVIATION 4.58 • n=83 Participants
|
49.62 millimeter
STANDARD_DEVIATION 5.27 • n=283 Participants
|
|
Echocardiographic Linear Dimensions
Left atrium transverse diameter
|
42.51 millimeter
STANDARD_DEVIATION 5.87 • n=157 Participants
|
42.84 millimeter
STANDARD_DEVIATION 4.07 • n=43 Participants
|
41.36 millimeter
STANDARD_DEVIATION 5.37 • n=83 Participants
|
42.22 millimeter
STANDARD_DEVIATION 5.50 • n=283 Participants
|
|
Left Ventricular Volume Index
|
64.87 milliliter per square meter (ml/m^2)
STANDARD_DEVIATION 20.53 • n=157 Participants
|
60.70 milliliter per square meter (ml/m^2)
STANDARD_DEVIATION 18.35 • n=43 Participants
|
56.04 milliliter per square meter (ml/m^2)
STANDARD_DEVIATION 10.58 • n=83 Participants
|
61.64 milliliter per square meter (ml/m^2)
STANDARD_DEVIATION 18.19 • n=283 Participants
|
|
Left Atrium Volume Index
|
37.45 millilitre per square meter (ml/m^2)
STANDARD_DEVIATION 5.89 • n=157 Participants
|
36.56 millilitre per square meter (ml/m^2)
STANDARD_DEVIATION 5.86 • n=43 Participants
|
37.47 millilitre per square meter (ml/m^2)
STANDARD_DEVIATION 5.41 • n=83 Participants
|
37.32 millilitre per square meter (ml/m^2)
STANDARD_DEVIATION 5.73 • n=283 Participants
|
|
Left Ventricular Mass Index
|
112.40 gram per square meter (g/m^2)
STANDARD_DEVIATION 22.08 • n=157 Participants
|
110.26 gram per square meter (g/m^2)
STANDARD_DEVIATION 23.92 • n=43 Participants
|
115.59 gram per square meter (g/m^2)
STANDARD_DEVIATION 27.90 • n=83 Participants
|
113.01 gram per square meter (g/m^2)
STANDARD_DEVIATION 24.18 • n=283 Participants
|
|
Left Ventricular Relative Wall Thickness
|
0.48 proportion in hundredths
STANDARD_DEVIATION 0.07 • n=157 Participants
|
0.49 proportion in hundredths
STANDARD_DEVIATION 0.06 • n=43 Participants
|
0.48 proportion in hundredths
STANDARD_DEVIATION 0.08 • n=83 Participants
|
0.48 proportion in hundredths
STANDARD_DEVIATION 0.07 • n=283 Participants
|
|
Left Ventricular Ejection Fraction
|
54.39 portion of volume in percent (%)
STANDARD_DEVIATION 6.32 • n=157 Participants
|
54.77 portion of volume in percent (%)
STANDARD_DEVIATION 5.58 • n=43 Participants
|
52.13 portion of volume in percent (%)
STANDARD_DEVIATION 6.12 • n=83 Participants
|
53.79 portion of volume in percent (%)
STANDARD_DEVIATION 6.23 • n=283 Participants
|
|
Tricuspid Annular Plane Systolic Excursion
|
21.03 millimeters
STANDARD_DEVIATION 2.77 • n=157 Participants
|
20.88 millimeters
STANDARD_DEVIATION 3.12 • n=43 Participants
|
20.83 millimeters
STANDARD_DEVIATION 2.21 • n=83 Participants
|
20.95 millimeters
STANDARD_DEVIATION 2.67 • n=283 Participants
|
|
Pulmonary Artery Systolic Pressure
|
38.22 millimetres of mercury (mmHg)
STANDARD_DEVIATION 8.67 • n=157 Participants
|
36.67 millimetres of mercury (mmHg)
STANDARD_DEVIATION 7.14 • n=43 Participants
|
36.47 millimetres of mercury (mmHg)
STANDARD_DEVIATION 7.77 • n=83 Participants
|
37.47 millimetres of mercury (mmHg)
STANDARD_DEVIATION 8.21 • n=283 Participants
|
|
Doppler- echocardiographic characteristics
Left ventricular hypertrophy
|
115 Participants
n=157 Participants
|
34 Participants
n=43 Participants
|
68 Participants
n=83 Participants
|
217 Participants
n=283 Participants
|
|
Doppler- echocardiographic characteristics
Increased left ventricular filling pressure
|
23 Participants
n=157 Participants
|
6 Participants
n=43 Participants
|
18 Participants
n=83 Participants
|
47 Participants
n=283 Participants
|
|
Doppler- echocardiographic characteristics
Right Ventricular Dilatation
|
20 Participants
n=157 Participants
|
5 Participants
n=43 Participants
|
20 Participants
n=83 Participants
|
45 Participants
n=283 Participants
|
|
Doppler- echocardiographic characteristics
Mitral annular calcification (MAC)
|
9 Participants
n=157 Participants
|
3 Participants
n=43 Participants
|
9 Participants
n=83 Participants
|
21 Participants
n=283 Participants
|
|
Doppler- echocardiographic characteristics
Secondary (functional) aortic regurgitation
|
24 Participants
n=157 Participants
|
17 Participants
n=43 Participants
|
41 Participants
n=83 Participants
|
82 Participants
n=283 Participants
|
|
Doppler- echocardiographic characteristics
Secondary (functional) tricuspid regurgitation
|
67 Participants
n=157 Participants
|
21 Participants
n=43 Participants
|
18 Participants
n=83 Participants
|
106 Participants
n=283 Participants
|
PRIMARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The event of death from any cause reported by the physician according to the WHO Clinical criteria for the determination of death or the incident declared by the caregiver of the patient and checked for appropriateness in hospital registries or the national death registry within the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Died From Any Cause (Death From Any Cause)
|
8 Participants
|
2 Participants
|
7 Participants
|
PRIMARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The event of death from any cardiovascular cause reported by the physician according the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions or the incident declared by the caregiver of the patient and checked for appropriateness in hospital registries or the national death registry within the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Died From Any Cardiovascular Cause (Death From Cardiovascular Cause)
|
5 Participants
|
1 Participants
|
6 Participants
|
PRIMARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The event of death from a non-cardiovascular cause reported by the physician or the incident declared by the caregiver of the patient and checked for appropriateness in hospital registries or the national death registry within the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Died From Non-cardiovascular Causes (Death From Non-cardiovascular Cause)
|
3 Participants
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of the non-fatal myocardial infarction detected during the study follow-up period and assessed by the 2012 Third Universal Definition of Myocardial Infarction as recommended by the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Non-fatal Myocardial Infarction (Non-fatal Myocardial Infarction)
|
4 Participants
|
1 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event corresponding to the unstable angina, or angina that requires hospitalization detected during the study follow-up period and assessed by the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Unstable Angina or Angina Requiring Hospitalization (Unstable Angina)
|
14 Participants
|
3 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of the stroke or transitory ischemic attack detected during the study follow-up period and assessed by the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions for Stroke and Transient Ischemic Attack during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced a Stroke or Transitory Cerebral Ischemic Event Within the Study Follow-up Period (Stroke or TIA)
|
5 Participants
|
1 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of major bleeding detected during the study follow-up period and assessed by the ARC-HBR (Academic Research Consortium for High Bleeding Risk) definitions as BARC type 3, 5 of bleeding during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Major Bleeding (Major Bleeding)
|
3 Participants
|
2 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of major bleeding detected during the study follow-up period and assessed by the ARC-HBR (Academic Research Consortium for High Bleeding Risk) definitions as BARC type 1 of bleeding during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Non-major Bleeding (Non-major Bleeding)
|
2 Participants
|
4 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of heart failure that requires hospitalization detected during the study follow-up period and assessed by the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Heart Failure Event (Heart Failure Event)
|
14 Participants
|
4 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The clinical event of any repeated coronary revascularization: percutaneous coronary intervention or coronary artery bypass-grafting detected during the study follow-up period and assessed by the SCTI (Standardized Data Collection for Cardiovascular Trials Initiative) definitions during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Participants Who Experienced Percutaneous Coronary Intervention or Coronary Artery Bypass-grafting (Repeated Coronary Revascularization)
|
17 Participants
|
4 Participants
|
16 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
Net adverse clinical event (NACE) is assessed via measuring and putting together death from any cause, non-fatal myocardial infarction, stroke/TIA, or major bleeding (BARC type 3, 5) as potential outcomes for every studied case during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Cases in Each Arm With a Composite of Death From Any Cause, Non-fatal Myocardial Infarction, Stroke/TIA, or Major Bleeding Within the Study Follow-up (Net Adverse Clinical Events - NACEs)
|
20 Participants
|
6 Participants
|
18 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
Major adverse cardiac or cerebral event (MACCE) is assessed by measuring and putting together death from cardiovascular cause, non-fatal myocardial infarction, or stroke/TIA as potential outcomes for every studied case during the study follow-up period, from the date of study enrollment until the date of the event.
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=142 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Cases in Each Study Arm With a Composite of Death From Any Cause, Myocardial Infarction, or Stroke/TIA Within the Study Follow-up (Major Adverse Cardiac or Cerebral Events - MACCEs)
|
17 Participants
|
4 Participants
|
14 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The number and percentage (%) of each arm of study participants treated with dual antiplatelet treatment, triple antiplatelet treatment, antiplatelet and non-vitamin K antagonist oral anticoagulant combination, or antiplatelet monotherapy
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=43 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
Number of Study Cases With Certain Antiplatelet Treatment Selection (Dual Antiplatelet Treatment, Triple Antiplatelet Treatment, Combined Antiplatelet and Anticoagulant, or Antiplatelet Monotherapy) in Each Study Arm
Dual Antiplatelet Treatment (DAPT)
|
114 Participants
|
27 Participants
|
72 Participants
|
|
Number of Study Cases With Certain Antiplatelet Treatment Selection (Dual Antiplatelet Treatment, Triple Antiplatelet Treatment, Combined Antiplatelet and Anticoagulant, or Antiplatelet Monotherapy) in Each Study Arm
Triple antiplatelet treatment
|
22 Participants
|
0 Participants
|
11 Participants
|
|
Number of Study Cases With Certain Antiplatelet Treatment Selection (Dual Antiplatelet Treatment, Triple Antiplatelet Treatment, Combined Antiplatelet and Anticoagulant, or Antiplatelet Monotherapy) in Each Study Arm
Combined antiplatelet and non-vitamin K antagonist oral anticoagulant (NOAC)
|
14 Participants
|
10 Participants
|
0 Participants
|
|
Number of Study Cases With Certain Antiplatelet Treatment Selection (Dual Antiplatelet Treatment, Triple Antiplatelet Treatment, Combined Antiplatelet and Anticoagulant, or Antiplatelet Monotherapy) in Each Study Arm
Antiplatelet monotherapy
|
7 Participants
|
6 Participants
|
0 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The number and percentage (%) of study participants treated with a certain antiplatelet drug - aspirin, clopidogrel, P2Y12 inhibitor alternative to clopidogrel, or a non-vitamin K antagonist oral anticoagulant (NOAC) in each study arm
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=43 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
The Number of Study Cases With Certain Antiplatelet Medication (Aspirin, Clopidogrel, P2Y12 Inhibitor, Alternative to Clopidogrel, or A Non-vitamin K Antagonist Oral Anticoagulant (NOAC)) Prescription
Aspirin
|
136 Participants
|
32 Participants
|
83 Participants
|
|
The Number of Study Cases With Certain Antiplatelet Medication (Aspirin, Clopidogrel, P2Y12 Inhibitor, Alternative to Clopidogrel, or A Non-vitamin K Antagonist Oral Anticoagulant (NOAC)) Prescription
Clopidogrel
|
157 Participants
|
0 Participants
|
83 Participants
|
|
The Number of Study Cases With Certain Antiplatelet Medication (Aspirin, Clopidogrel, P2Y12 Inhibitor, Alternative to Clopidogrel, or A Non-vitamin K Antagonist Oral Anticoagulant (NOAC)) Prescription
P2Y12 inhibitor, alternative to Clopidogrel
|
0 Participants
|
38 Participants
|
0 Participants
|
|
The Number of Study Cases With Certain Antiplatelet Medication (Aspirin, Clopidogrel, P2Y12 Inhibitor, Alternative to Clopidogrel, or A Non-vitamin K Antagonist Oral Anticoagulant (NOAC)) Prescription
Non-vitamin K antagonist oral anticoagulant (NOAC)
|
36 Participants
|
10 Participants
|
11 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The number and percentage (%) of study participants treated with lipid-lowering medication - statin, or combined statin and ezetimibe, or statin, ezetimibe and PCSK9i in each study arm
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=43 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
The Number of Study Cases With Lipid-lowering Medication (Statin, or Combination With Ezetimibe, or Ezetimibe and PCSK9i) Prescription
Statin
|
87 Participants
|
27 Participants
|
21 Participants
|
|
The Number of Study Cases With Lipid-lowering Medication (Statin, or Combination With Ezetimibe, or Ezetimibe and PCSK9i) Prescription
Combined statin and ezetimibe
|
67 Participants
|
16 Participants
|
62 Participants
|
|
The Number of Study Cases With Lipid-lowering Medication (Statin, or Combination With Ezetimibe, or Ezetimibe and PCSK9i) Prescription
Combined statin, ezetimibe and PCSK9i
|
3 Participants
|
0 Participants
|
0 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The number and percentage (%) of study participants treated with certain hypoglycemic medication - insulin, sodium-glucose cotransporter-2 (SGLT2) inhibitor, metformin, glucagon-like peptide-1 (GLP-1) receptor agonist, or dipeptidyl peptidase IV (DPP IV) inhibitor in each study arm
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=43 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
The Number of Study Cases With Hypoglycemic Medication Prescription
Metformin
|
39 Participants
|
12 Participants
|
31 Participants
|
|
The Number of Study Cases With Hypoglycemic Medication Prescription
Dipeptidyl peptidase IV (DPP IV) inhibitor
|
31 Participants
|
10 Participants
|
30 Participants
|
|
The Number of Study Cases With Hypoglycemic Medication Prescription
Insulin
|
4 Participants
|
2 Participants
|
4 Participants
|
|
The Number of Study Cases With Hypoglycemic Medication Prescription
Sodium-glucose cotransporter-2 (SGLT2) inhibitor
|
81 Participants
|
23 Participants
|
43 Participants
|
|
The Number of Study Cases With Hypoglycemic Medication Prescription
Glucagon-like peptide-1 (GLP-1) receptor agonist
|
3 Participants
|
0 Participants
|
0 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: within a 12-month of the study follow-upPopulation: Study participants of both sexes aged 35-79 years old, diagnosed with chronic coronary artery disease, who had undergone elective PCI and required P2Y12 inhibitor antiplatelet treatment
The number and percentage (%) of study participants treated with other common evidence-based medication for cardiovascular risk reduction - angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNi), beta adrenergic blocker, loop diuretic, mineralocorticoid receptor antagonist (MCRA), thiazide diuretic, calcium channel blocker, anti-arrhythmic drug or ivabradine in each study arm
Outcome measures
| Measure |
Normal Metabolizers of Clopidogrel
n=157 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=43 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=83 Participants
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype was not specified
|
|---|---|---|---|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Loop diuretic
|
43 Participants
|
8 Participants
|
31 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Angiotensin converting enzyme inhibitor (ACEi)
|
47 Participants
|
13 Participants
|
51 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Angiotensin receptor blocker (ARB)
|
83 Participants
|
22 Participants
|
24 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Angiotensin receptor neprilysin Inhibitor (ARNi)
|
21 Participants
|
7 Participants
|
20 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Beta adrenergic blocker
|
129 Participants
|
34 Participants
|
80 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Mineralocorticoid receptor antagonist (MCRA)
|
47 Participants
|
15 Participants
|
26 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Thiazide diuretic
|
32 Participants
|
5 Participants
|
37 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Calcium channel blocker
|
58 Participants
|
13 Participants
|
32 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Anti-arrhythmic drug
|
22 Participants
|
11 Participants
|
3 Participants
|
|
The Number of Study Cases With Other Common Evidence-Based Medication Prescription for Cardiovascular Risk Reduction
Ivabradine
|
4 Participants
|
1 Participants
|
0 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: at 3, 6 and 12-month of the study follow-upThe health status reported by the patient as: a) good or satisfactory; b) with the appearance of CVD symptoms; c) a significant inability to self-care ranked with severity degree of patient well-being, symptom burden, or ability for self-care, which is assessed according to the routine health related quality of life questionnaire definitions.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: at 3, 6 and 12-month of the study follow-upThe participant-reported last week episode of chest pain, or any discomfort, shortness of breath, or tightness in the chest due to angina not required hospitalization assessed by the CROQ (Coronary Revascularization Outcome Questionnaire) definitions.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: at 3, 6 and 12 months of the study follow-upThe participant reported last week's shortness of breath due to mild physical activity or at rest not requiring hospitalization assessed by the PROMIS®-Plus-HF (Patient-Reported Outcomes Measurement Information System®-Plus-Heart Failure) profile definitions.
Outcome measures
Outcome data not reported
Adverse Events
Normal Metabolizers of Clopidogrel
Serious events: 23 serious events
Other events: 4 other events
Deaths: 8 deaths
Passive Metabolizers of Clopidogrel
Serious events: 10 serious events
Other events: 4 other events
Deaths: 2 deaths
Unspecified Metabolizers of Clopidogrel
Serious events: 25 serious events
Other events: 5 other events
Deaths: 7 deaths
Serious adverse events
| Measure |
Normal Metabolizers of Clopidogrel
n=142 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype has not been specified
|
|---|---|---|---|
|
Blood and lymphatic system disorders
Major Bleeding
|
2.1%
3/142 • Number of events 3 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
5.3%
2/38 • Number of events 2 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
5.7%
4/70 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
1.4%
2/142 • Number of events 2 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
2.6%
1/38 • Number of events 1 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
2.9%
2/70 • Number of events 2 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Cardiac disorders
Non-fatal Myocardial Infarction
|
2.8%
4/142 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
2.6%
1/38 • Number of events 1 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
5.7%
4/70 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Cardiac disorders
Unstable Angina or Angina Requiring Hospitalization
|
5.6%
8/142 • Number of events 14 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
7.9%
3/38 • Number of events 3 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
14.3%
10/70 • Number of events 16 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Vascular disorders
Stroke or Transitory Cerebral Ischemic Event
|
3.5%
5/142 • Number of events 5 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
2.6%
1/38 • Number of events 1 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
4.3%
3/70 • Number of events 3 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Cardiac disorders
Heart Failure Event
|
0.70%
1/142 • Number of events 14 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
5.3%
2/38 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
2.9%
2/70 • Number of events 9 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
Other adverse events
| Measure |
Normal Metabolizers of Clopidogrel
n=142 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping and identified as NFA \*2, \*3 carriers. CYP2C19 Genotype-Guided Clopidogrel Treatment Clopidogrel as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT), or an antiplatelet drug (clopidogrel) combined with the non-vitamin K antagonist oral anticoagulants (NOAC), incl. triple antiplatelet treatment (Aspirin, Clopidogrel and a NOAC), or antiplatelet monotherapy (Clopidogrel)
|
Passive Metabolizers of Clopidogrel
n=38 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI, tested with CYP2C19 genotyping were identified as LoF \*2, \*3 allele carriers. CYP2C19 Genotype Guided Antiplatelet Treatment alternative to clopidogrel in conventional dosing regimen, as a component of preventive antiplatelet treatment, such as double antiplatelet treatment (DAPT) with ticagrelor or prasugrel, or prasugrel combined with the nonvitamin K antagonist oral anticoagulants (NOAC), or antiplatelet monotherapy (ticagrelor or prasugrel).
|
Unspecified Metabolizers of Clopidogrel
n=70 participants at risk
Study participants diagnosed with chronic coronary artery disease who had undergone elective PCI were allocated to the arm through the randomisation, without CYP2C19 genotyping and clopidogrel metabolism phenotype has not been specified
|
|---|---|---|---|
|
Blood and lymphatic system disorders
Minor bleeding
|
1.4%
2/142 • Number of events 2 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
10.5%
4/38 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
5.7%
4/70 • Number of events 4 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
|
Skin and subcutaneous tissue disorders
Skin Rashes and Itching
|
1.4%
2/142 • Number of events 2 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
0.00%
0/38 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
1.4%
1/70 • Number of events 1 • 12-month period of the study follow-up
The data for adverse events were collected from the 250 participants who completed the study. The study routinely collects information on Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs) that are severe in terms of their outcome and considered as clinical endpoints of the study. They are presented in the study outcomes section as well.
|
Additional Information
Konstantine Liluashvili , MD., PH.D.
Tbilisi State Medical University
Phone: +995599908899
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place